Legend Biotech Investor Presentation — December 2021

Document content

December 2021Disclaimer

This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information

relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been establishe d. There is no guarantee that the agents will receive health

authority approval or become commercially available in any country for the uses being investigated.

Certain information contained in this presentation and statements made orally during this presentation relate to or arebased on studies, publications, surveys and other data obtained

from third -party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third -party sources to be reliable as of the date of this

presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or comple teness of, any information obtained from third -party

sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independ entsource.

Forward -Looking Statements

This presentation contains “forward -looking statements” within the meaning of The Private Securities Litigation Reform Act of 19 95. The words “anticipate,” “believe,” “continue,” “could,”

“estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and sim ilar expressions are intended to identify forward -looking statements,

although not all forward -looking statements contain these identifying words.

These forward -looking statements include, but are not limited to, statements relating to the Company’s strategies and objectives ; the anticipated timing of, and ability to progress,

clinical trials; the ability to make, and the timing of, regulatory submissions in the United States, Europe and Asia, includ ingBiologics License Application (BLA) submission to the U.S.

Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel) for relapsed or refractory multiple myeloma (RRMM), the submission of a marketing authorisation

application (MAA) for cilta-celto the European M edicines Agency ( EMA), and the submission of an Investigational New Drug (IND) for LB1901 in relapsed or refractory T -Cell

Lymphoma (TCL); the ability to generate, analyze and present data from clinical trials; patient enrollment; anticipated timin g regarding regulatory approvals by the FDA, EMA or Center

for Drug Evaluation (CDE); and the potential benefits of Legend Biotech’s product candidates. Actual results may differ mater ially from those indicated by such forward -looking